Passage Bio (PASG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 18, 2026.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms: Athena Countouriotis, M.D. and Sandip Kapadia.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Advisory vote on the frequency of future say-on-pay votes.
Consideration of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Latest events from Passage Bio
- PBFT02 gene therapy shows durable biomarker response and early disease-modifying potential in FTD-GRN.PASG
Corporate presentation20 Apr 2026 - Shareholders will vote on directors, auditor, and executive pay, with strong governance and ESG focus.PASG
Proxy filing7 Apr 2026 - Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning.PASG
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - PBFT02 delivers durable PGRN elevation in FTD-GRN, with strong safety and pipeline progress.PASG
Corporate presentation3 Mar 2026 - Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027.PASG
Q4 20253 Mar 2026 - Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024.PASG
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - One-time gene therapy PBFT02 shows durable target engagement and advances toward pivotal trials.PASG
Leerink Global Healthcare Conference 20253 Feb 2026 - PBFT02 delivers durable, high CSF progranulin in FTD-GRN, with expansion to other neurodegenerative diseases planned.PASG
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Gene therapy for FTD shows strong efficacy and safety, with pivotal data expected in 2025.PASG
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026